Message From the Editor-in-Chief
Message From the Editor-in-Chief ― Circulation Reports Is Entering Its 6th Year ―
2024 Volume 6 Issue 1 Pages 1-3
Details
2024 Volume 6 Issue 1 Pages 1-3
Dear Colleagues,
Welcome to the first issue of the Circulation Reports (Circ Rep) for 2024. On January 10, 2019, Circ Rep, a sister journal to Circulation Journal, was launched as an official journal of the Japanese Circulation Society. During these 5 years, we have had great success by publishing many interesting papers not only from Japan, but also from all over the world. On March 12, 2021, all papers published in Circ Rep became searchable in PubMed Central®. The editorial team are doing everything they can to obtain an impact factor for Circ Rep as soon as possible.
Here, I would like to take the opportunity to summarize the progress of Circ Rep in 2023.
Figure 1 shows the number of manuscripts submitted to the Journal. We are receiving approximately 10 manuscripts each month. As of December 8, 2023, 95 manuscripts had been submitted in 2023: 65.2% were de novo submissions and 34.8% were transferred from Circulation Journal. Figure 2 shows the types of manuscripts submitted. Clinical Investigation and Images in Cardiovascular Medicine are the major categories. We published 1 Protocol Paper and 4 Rapid Communications, which are unique categories in this Journal. Figure 3 shows the countries from which manuscripts have been submitted. Although submissions from Japan dominate, we have received 1 manuscript from United States and 2 manuscripts from Portugal.
Number of manuscripts submitted to Circulation Reports each month in 2023.
Types of manuscripts submitted to Circulation Reports in 2023.
Countries from which manuscripts were submitted to Circulation Reports in 2023.
The acceptance rate is 64.6%. Most of the manuscripts transferred from Circulation Journal have been accepted without delay after the Editor-in-Chief carefully checked the revised manuscripts and the author’s replies to the original reviewers. In 2023, the average time from submission to acceptance was 36.2 days. The average time from acceptance to advance online publication was 26.3 days. The editorial team continues efforts to minimize the time from submission to publication.
Circ Rep published 79 excellent papers in 2023. The top 10 papers most frequently viewed are summarized in the Table.
Top 10 Frequently Viewed Papers
| Rank | AccessA | Paper |
|---|---|---|
| 1 | 1,658 | Matsukawa R, Okahara A, Tokutome M, Itonaga J, Hara A, Kisanuki K, et al. Early initiation of sodium–glucose cotransporter 2 inhibitor leads to a shorter hospital stay in patients with acute decompensated heart failure. Circ Rep 2023; 5: 187–197, doi:10.1253/circrep.CR-22-0118. |
| 2 | 1,589 | Katano S, Yano T, Numazawa R, Nagaoka R, Yamano K, Fujisawa Y, et al. Impact of radar chart-based information sharing in a multidisciplinary team on in-hospital outcomes and prognosis in older patients with heart failure. Circ Rep 2023; 5: 271–281, doi:10.1253/circrep.CR-23-0049. |
| 3 | 1,499 | Masumori N, Nakatsuka M. Cardiovascular risk in transgender people with gender-affirming hormone treatment. Circ Rep 2023; 5: 105–113, doi:10.1253/circrep.CR-23-0021. |
| 4 | 1,490 | Yamashita M, Matsuzawa R, Kondo H, Kanata Y, Sakamoto R, Tamaki A. Heart failure management capability and exacerbation of heart failure: A 6-month prospective cohort study. Circ Rep 2023; 5: 245–251, doi:10.1253/circrep. CR-23-0042. |
| 5 | 1,380 | Suwa M, Nohara Y, Morii I, Kino M. Safety and efficacy re-evaluation of edoxaban and rivaroxaban dosing with plasma concentration monitoring in non-valvular atrial fibrillation: With observations of on-label and off-label dosing. Circ Rep 2023; 5: 80–89, doi:10.1253/circrep.CR-22-0076. |
| 6 | 1,309 | Mizuno Y, Ishida T, Kugimiya F, Takai S, Nakayama Y, Yonemitsu K, et al. Deterioration of phosphate homeostasis is a trigger for cardiac afterload: Clinical importance of fibroblast growth factor 23 for accelerated aging. Circ Rep 2023; 5: 4–12, doi:10.1253/circrep.CR-22-0124. |
| 7 | 1,187 | Nakamura T, Nakamura M, Kai M, Shibasaki Y, Tomita H, Watabe M, et al. Clinical use of oral opioid therapy for dyspnea in patients with advanced heart failure: A single-center retrospective study. Circ Rep 2023; 5: 351–357, doi:10.1253/circrep.CR-23-0059. |
| 8 | 1,176 | Shiraishi Y, Kurita Y, Matsukawa M, Mori H. Real-world intravenous diuretic use to treat congestion in patients with heart failure: An observational study using a research database. Circ Rep 2023; 5: 27–37, doi:10.1253/circrep. CR-22-0091. |
| 9 | 1,161 | Suzuki T, Mizuno A, Kishi T, Rewley J, Matsumoto C, Sahashi Y, et al. Impact of tweet content on the number of retweets: “Tweet the Meeting 2022”. Circ Rep 2023; 5: 306–310, doi:10.1253/circrep.CR-23-0043. |
| 10 | 1,160 | Miwa K. Orthostatic intolerance and chronotropic incompetence in patients with myalgic encephalomyelitis or chronic fatigue syndrome. Circ Rep 2023; 5: 55–61, doi:10.1253/circrep.CR-22-0114. |
AThe number of times the online journal bibliographic information has been viewed over the past 1 year.
Once again, I would like to emphasize that the editorial team is doing its best to get an impact factor for Circ Rep soon. Finally, I acknowledge all associate editors and reviewers for their excellent, quick work and commitment to reviewing the manuscripts. I also thank the secretaries in the editorial office for their continuous supports. I hope that more and more manuscripts will be submitted from all over the world this year.
